Type of non Hodgkin's lymphoma-Other-Lymphoplasmacytic lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Other-Lymphoplasmacytic lymphoma Posts on Medivizor

Evaluating the effectiveness of longer-term rituximab maintenance therapy in patients with painless non-Hodgkin lymphoma.

Evaluating the effectiveness of longer-term rituximab maintenance therapy in patients with painless non-Hodgkin lymphoma.

Posted by on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the effectiveness and safety of longer rituximab (Rituxan) maintenance therapy schedules (more than 2 years) for the treatment of patients with relapsed or refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that maintenance for up to 2 years with rituximab after response to...

Read More

Treating patients with B-cell non-Hodgkin lymphoma with immunoglobulin replacement therapy after rituximab treatment

Treating patients with B-cell non-Hodgkin lymphoma with immunoglobulin replacement therapy after rituximab treatment

Posted by on Sep 6, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the outcomes of immunoglobulin replacement (IgR) therapy in patients with B-cell non-Hodgkin lymphoma (B-NHL) and immunodeficiency, who were previously treated with rituximab (Rituxan). The authors found that IgR was safe and effective to increase serum immunoglobulins in such patients. Some background B-NHL happens...

Read More

Searching for participants to try a new combination of targeted therapy for relapsed or non-responsive B-cell lymphomas.

Posted by on May 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is investigating the effectiveness of a new combination of treatments, nivolumab (Opdivo) and varlilumab (CDX-1127), for non-responsive, aggressive B-cell lymphomas. The main outcome that will be measured is the proportion of patients that respond to treatment (overall response rate). This trial is recruiting in the US. The...

Read More

Predicting the effects of stem cell transplant in older patients with non-Hodgkin lymphoma.

Posted by on Feb 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of stem cell transplant for non-Hodgkin lymphoma (NHL) in older patients. The main finding was that patients who responded to chemotherapy had better outcomes after stem cell transplant. Some background Stem cell transplant is often used to treat NHL. This involves the transfer of healthy cells to a...

Read More

Evaluating lenalidomide plus everolimus for relapsed or refractory lymphoma

Posted by on Oct 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of lenalidomide (Revlimid) plus everolimus (Afinitor) in pretreated patients with relapsed (recurrent) or refractory (does not respond to treatment) lymphoma. This study concluded that this combination was well-tolerated and showed promising effectiveness in these patients. Some...

Read More

Evaluating the impact of adding combination antiretroviral therapy to chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma

Posted by on Sep 8, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...

Read More

Comparing health related quality of life between indolent non-Hodgkin lymphoma patients treated with obinutuzumab plus bendamustine vs bendamustine alone

Posted by on Oct 24, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the quality of life between indolent non-Hodgkin lymphoma patients who are treated with obinutuzumab plus bendamustine or bendamustine alone. The study concluded that patients treated with obinutuzumab plus bendamustine experience prolonged quality of life compared to patients treated with bendamustine...

Read More

Looking for patients to test CAR T-cells in treating relapsed or refractory indolent non-Hodgkin lymphoma

Posted by on Aug 29, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate.   The details Axicabtagene ciloleucel is a chimeric antigen...

Read More